Objective-Reendothelialization after vascular injury (ie, balloon angioplasty or stent implantation) is clinically extremely relevant to promote vascular healing. We here investigated the therapeutic potential of the toll-like receptor 2/6 agonist macrophageactivating lipopeptide (MALP)-2 on reendothelialization and neointima formation in a murine model of vascular injury. Approach and Results-The left common carotid artery was electrically injured, and reendothelialization was quantified by Evans blue staining after 3 days. A single injection of MALP-2 (1 or 10 µg, IV) after vascular injury accelerated reendothelialization (P<0.001). Proliferation of endothelial cells at the wound margins determined by 5-ethynyl-2′-deoxyuridine incorporation was significantly higher in MALP-2-treated animals (P<0.05). 
I
nterventional angioplasty procedures for revascularization of patients with coronary artery disease or peripheral artery disease have dramatically increased during the past 3 decades and are still in progress. 1, 2 However, techniques such as balloon angioplasty and stent implantation provoke a massive disruption of the vascular integrity, thus requiring vascular wound healing including reendothelialization. Particularly, insufficient or decelerated reendothelialization amplifies vascular inflammation and impairs vascular wound healing, thereby increasing the risk of clinically fatal events, such as stent thrombosis and restenosis. Despite novel drug-eluting stent technologies, in the majority of cases with anti-inflammatory/ antiproliferative substances, restenosis as a result of inflammation-driven proliferation of smooth muscle cells with subsequent neointima formation is still a clinical problem. 3 Because of their antiproliferative nature, the widely used drugs not only suppress neointima formation but also retard reendothelialization. Because incompletely reendothelialized vessels are highly thrombogenic, extended dual platelet aggregation inhibition with consecutively increased bleeding risk in those patients is needed.
pathogen-associated molecular patterns of bacterial and viral origin to organize the body's immune defense. 5 More than 10 members were identified so far activating classical inflammatory signaling pathways, such as the mitogen-activated protein kinase (MAPK) cascade or nuclear factor-κB. 6 Especially monocytes/ macrophages and granulocytes are stimulated by TLR ligands to produce reactive oxygen species, cytokines, and costimulatory molecules for pathogen killing and clearance. Their important role in dendritic cell maturation and T-cell activation established TLRs as an important link between innate and adaptive immunity. 7 The detection of TLR members in multiple tissues and cell types, besides cells of the immune system, put a new complexion on TLRs. Inflammatory disorders, such as atherosclerosis 8 and liver disease, 9 are critically influenced by TLR signaling. In this regard, the ability of TLRs to recognize endogenous ligands that accumulate during tissue damage and fibrosis has already been discovered and seems to be essential for their function in regulating noninfectious inflammation. 10 Of importance, a novel role of TLRs in wound healing 11, 12 and tissue regeneration 13, 14 has been reported, also indicating a regenerative aspect of TLR signaling.
We here used the N-terminal diacetylated lipopeptide macrophage-activating lipopeptide of 2 kDa (MALP-2) that was originally isolated from Mycoplasma species. 15 MALP-2 is recognized by a heterodimer of TLR2 and TLR6 16, 17 and is to date one of the few definitely identified natural ligands signaling via this pathway. Initial studies were performed in cells of the innate immune system, that is, macrophages. Of note, immune activation with MALP-2 has potential therapeutic implications, for example, as a mucosal adjuvant for vaccination 18 or for the induction of lipopolysaccharide cross-tolerance. 19 Furthermore, MALP-2 also exhibits potential for regenerative processes because MALP-2 has already been successfully used to promote dermal wound healing in mice. 11 Wound repair involves not only recruitment of inflammatory cells but also the reestablishment of a capillary network by endothelial cells, termed angiogenesis. In this regard, we recently reported that MALP-2 exhibits a considerable potential to induce angiogenesis in a TLR2/6-dependent manner, which represents an endogenous mechanism to restore capillaries in infected tissues to recruit immune cells for pathogen defense. 20 The luminal endothelium plays a critical role in the regulation of the vascular permeability, cellular adhesion to the arterial wall, and the local production of growth factors. Thus, injury to the luminal endothelium, either metabolic or mechanical, definitely results in a misbalance of these important features. 21 Because we already established endothelial cells as target cells for a TLR2/6-dependent pathway, we now investigated a potential therapeutic application of MALP-2 to promote luminal reendothelialization after vascular injury.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

MALP-2 Promotes Reendothelialization After Vascular Electric Injury
To induce an endothelial damage, we performed an electric injury of the left common carotid artery in C57BL/6N wild-type mice, a precise and reliable method to determine reendothelialization ( Figure IA in the online-only Data supplement). Subsequently, 2 hours after injury, either 1 or 10 µg MALP-2 was injected (intravenously), and reendothelialization was quantified on Evans blue-stained en face prepared carotid arteries 3 days after injury by morphometric analysis. Compared with the initial wound area, we observed 7.9% reendothelialization under control conditions, which was significantly enhanced by MALP-2 treatment to 23.7% (1 µg; P<0.001) and 28.9% (10 µg; P<0.001). Of note, MALP-2 treatment enhanced reendothelialization ≤3.5-fold. Combined injection of neutralizing antibodies against the MALP-2 receptors TLR2 and TLR6 significantly suppressed MALP-2-induced reendothelialization (P<0.001), proving the relevance of the TLR2/6-dependent pathway for MALP-2-induced endothelial regeneration ( Figure 1A ). In addition, we investigated reendothelialization in response to different other TLR ligands. However, neither Pam 2 CSK 4 that signals via TLR2/6 just as MALP-2 nor the TLR2/1 agonist Pam 3 CSK 4 nor the TLR4 agonist LPS promoted reendothelialization in this model ( Figure II in the online-only Data Supplement). Obviously, this effect is not a class effect of TLR agonists and not even characteristic of TLR2/6 agonists. Next, we investigated whether enhanced proliferation of endothelial cells is responsible for MALP-2-induced reendothelialization after vascular injury. Therefore, we analyzed cell proliferation at the endothelial wound margins in en face prepared carotid arteries ( Figure IB in the online-only Data Supplement) 3 days after injury by quantifying 5-ethynyl-2′-deoxyuridine incorporation using confocal microscopy. Proliferating 5-ethynyl-2′-deoxyuridinepositive cells could be clearly identified as endothelial cells by immunofluorescent staining of the endothelial marker CD31. Indeed, compared with control conditions, MALP-2 significantly enhanced endothelial cell proliferation at the denuded wound margins (P<0.05; Figure 1B ).
MALP-2 Inhibits Neointima Formation After Vascular Wire Injury
The method of perivascular electric injury is mainly used to investigate reendothelialization of the carotid artery, where normally no neointima formation is observed. 22, 23 However, because MALP-2 seems to have highly proliferative properties, we likewise took the possibility of MALP-2-induced smooth muscle proliferation even in this model into consideration. To this end, we investigated the morphology of the carotid artery ≤28 days after electric injury. Morphometric analyses in hematoxylin and eosin-stained cross sections of the injured carotid artery right in the middle of the initial injury ( Figure IC in the online-only Data Supplement) revealed no abnormalities under control or MALP-2 conditions. We did not detect any neointima or media hyperplasia or other signs of maladaptive vascular remodeling ( Figure IIIA To address especially neointima proliferation, we took advantage of the vascular wire injury model in FVB/N mice. 24 Wire injury was performed at the same site of the left common carotid artery as before in the electric injury model ( Figure  IA in the online-only Data Supplement). Subsequently, 10 µg MALP-2 was administered 2 hours after injury (intravenously), and morphometric analysis was performed on hematoxylin and eosin-stained cross sections of the carotid artery 28 days later. Of note, wire injury-induced neointima formation was completely inhibited on MALP-2 treatment ( Figure 2 ). In addition, MALP-2 did not induce platelet aggregation of human platelet-rich plasma ( Figure IV in the onlineonly Data Supplement), suggesting that adverse effects on thrombosis after MALP-2 treatment are not to be expected.
MALP-2 Enhances In Vitro Wound Closure and Proliferation of Endothelial Cells But Not Smooth Muscle Cells
To study cellular processes that are presumably involved in enhanced reendothelialization after MALP-2 injection, we studied proliferation and migration of endothelial cells in response to MALP-2 in vitro. Although MALP-2 treatment did not provoke neointimal proliferation in vivo, we likewise expanded our in vitro studies to smooth muscle cells to further study potentially undesirable side effects of MALP-2 in this regard. Similar to the in vivo situation, MALP-2 accelerated the closure of an artificial wound scratch in endothelial cells 24, 48, and 72 hours after experimental induction of the wound compared with control conditions (P<0.05; Figure 3A ). However, we did not observe any significant effect of MALP-2 to enhance the ability of smooth muscle cells to close the artificial wound ( Figure 3B ). Of note, during an observation period of 3 days, wound closure in this model implies both cell migration and cell proliferation. To address particularly cell proliferation, we additionally investigated nuclear BrdU incorporation. Consistent with the scratch experiments, we observed similar effects of MALP-2 on these vascular cell types. Compared with control, stimulation with MALP-2 for 24 hours increased proliferation of endothelial cells (P<0.05; Figure 3C ) but not of smooth muscle cells ( Figure 3D ).
MALP-2 Stimulates the Release of Growth Factors and Cytokines and MAPK Cascade Activation in Endothelial Cells
During vascular injury and endothelial denudation, smooth muscle cells are uncovered and unnaturally exposed to the blood flow in the carotid artery. Thus, circulating MALP-2 could activate TLR2 and TLR6 on endothelial cells and smooth muscle cells to initiate a regenerative program of local endothelial wound healing. To investigate which of these vascular cell types may release factors as a potential underlying mechanism for reendothelialization in response to MALP-2, we isolated primary endothelial cells and smooth muscle cells. Protein array analyses for selected cytokines and growth factors revealed that endothelial cells released numerous factors on MALP-2 stimulation. In contrast, these factors were not enhanced or even downregulated by MALP-2 stimulation in smooth muscle cells ( Figure 4A ). In addition, we performed ELISA analyses to validate the protein array data. Therefore, we investigated granulocyte colony-stimulating factor (G-CSF) and interleukin-6, which were the most prominent MALP-2-induced factors in endothelial cells. In fact, we were able to confirm the results of the protein array. MALP-2 significantly enhanced the secretion of G-CSF ( Figure 4B ) and interleukin-6 ( Figure 4C ) from endothelial cells (P<0.05), whereas MALP-2 had no effect on G-CSF and interleukin-6 secretion from smooth muscle cells. Expression of both MALP-2 receptors was detected in endothelial cells and smooth muscle cells, although TLR6 was found to be only weakly expressed in smooth muscle cells ( Figure 4D ).
Endothelial cells seem to be the main vascular source of soluble factors mediating the regenerative effects of MALP-2 after vascular injury. To further address this issue, we isolated the left carotid artery immediately after injury and at the same time the noninjured right carotid artery. Both vessels were dissected and subsequently cultured and stimulated with MALP-2 ex vivo. Secretion of numerous investigated factors was strongly induced by MALP-2 in vessels with an intact endothelium and either attenuated or downregulated in vessels with endothelial damage ( Figure 5A ). Again, we confirmed the strongest MALP-2-induced factors by ELISA, which were G-CSF and granulocyte macrophage colony-stimulating factor. Secretion of both growth factors was induced after MALP-2 stimulation in the noninjured carotid artery that was significantly less pronounced in the injured carotid artery (P<0.05; Figure 5B and 5C).
Furthermore, we investigated MAPK signaling in isolated murine endothelial cells and smooth muscle cells in response to MALP-2 by Western blot. All 3 major pathways, the extracellular signal-regulated kinase 1/2, p38 MAPK, and c-Jun N-terminal kinase, were strongly induced in endothelial cells on MALP-2 stimulation, with a maximal peak ≈15 minutes. Interestingly, MALP-2-dependent MAPK activation was attenuated and decelerated in smooth muscle cells (Figure 6A-6C ).
MALP-2 Increases Numbers of Circulating Monocytes, Granulocytes, and Progenitor Cells
Because leukocyte subsets and progenitors cells have been shown to contribute to vascular wound healing, we additionally investigated the effect of MALP-2 on peripheral blood levels of these cell populations. 
Discussion
Endothelial cells play a pivotal role in vascular homeostasis. The endothelium produces nitric oxide for vasorelaxation, controls leukocyte adherence, regulates vascular permeability, and much more. 21 In this regard, endothelial dysfunction is an initial event in arterial hypertension, atherosclerosis, and diabetes mellitus. 25 All kinds of interventional angioplasty techniques induce massive vascular injuries, including extensive endothelial damage. Therefore, cardiologists have to deal with the consequences of revascularization in patients with coronary artery disease or peripheral artery disease because vascular injury results in severe vascular inflammation. Insufficient or delayed reendothelialization further aggravates and extends vascular inflammation and wound healing in these patients (as known from drug-eluting stents). The inflammatory process includes activation of inflammatory signaling pathways, enhanced expression of cellular and soluble adhesion molecules, local release of cytokines and chemokines, and enhanced generation of reactive oxygen species in the vessel wall. 21 A major problem of this exaggerated inflammation is the neointima formation because of excessive proliferation of smooth muscle cells from the media bearing the risk of stent thrombosis and restenosis. Therefore, drug-eluting stent technologies using antiproliferative substances, such as sirolimus or paclitaxel, are frequently being used to inhibit excessive smooth muscle cell proliferation and thereby neointima formation and restenosis. 3 The drawback of these drugs is a further retarded reendothelialization requiring a dual antiplatelet aggregation therapy, usually with aspirin and P2Y12 inhibitors, for ≤1 year to prevent coagulation at sites of vascular injury. 4 Until now, studies testing substances to improve reendothelialization are very rare. We here describe for the first time that a TLR agonist significantly improves reendothelialization.
TLRs represent a major protein receptor class of pattern recognition receptors of the innate immunity with fundamental functions for pathogen recognition. 5 However, TLRs are likewise activated by danger-associated molecular patterns that do not only include bacterial and viral pathogen-associated molecular patterns but also a variety of endogenous substances, such as proteins, peptides, polysaccharides, proteoglycans, nucleic acids, and phospholipids. The latter are particularly extracellular matrix degradation products that accumulate after tissue damage. Thus, TLRs are activated not only in response to tissue-invading pathogens but are also pathogen independent, for example, after tissue damage or ischemic conditions. In both cases, TLRs have important functions in the recruitment of immune cells to initiate a regenerative program: in the first case mainly to eliminate invading pathogens and in the second case to clear the affected tissue from apoptotic cells and cellular debris.
With respect to the cardiovascular system, TLR2 and TLR4 expression has been documented in cardiomyocytes, endothelial cells, and smooth muscle cells. 26, 27 Accumulating evidence, in most instances from genetically modified mouse models, suggests that TLRs play important roles in different cardiovascular pathologies, such as septic cardiomyopathy, viral myocarditis, atherosclerosis, ischemia/reperfusion injury after myocardial infarction, dilated cardiomyopathy, and cardiac allograft rejection. 28 These disorders are of noninfectious cause, and inflammatory pathways are triggered by endogenous TLR ligands that usually accumulate under these conditions. Experimental loss-of-function studies, mainly on TLR2 and TLR4, demonstrated that inhibition of TLRs has beneficial effects on the pathology of atherosclerosis and on ischemia/ reperfusion injury after myocardial infarction. [29] [30] [31] This is in accordance with findings that prolonged administration of TLR2 agonists dramatically increases experimental atherosclerosis. 31 Prolonged TLR3 activation by polyI:C has even been shown to impair reendothelialization and endothelial function, finally aggravating atherosclerosis. 32 In contrast, unique and selective pretreatment with TLR2 or TLR4 ligands reduced infarct size and improved cardiac function after ischemia/reperfusion. 33, 34 To date, different TLR ligands (eg, TLR9) have been described to accelerate wound healing involving angiogenesis by endothelial cells. 35 These data suggest an ambivalent role for TLRs in cardiovascular pathology. On the one hand, sustained TLR stimulation exacerbates inflammation. Therefore, blockade of TLRs may represent a promising strategy for therapeutic intervention. On the other hand, administration of defined TLR agonists in a timely controlled and limited manner could have beneficial effects. This may occur via a singular inflammatory trigger that initiates regenerative pathways, and this strategy could even be used for preconditioning.
We here used the lipopeptide MALP-2 that represents a wellcharacterized TLR agonist with already reported regenerative properties. The synthesis of the compound is completely synthetical, 15 excluding contaminations with other TLR agonists, a well-known problem in the field. Initially, MALP-2 was shown to stimulate mainly cells of the innate immunity by binding to a heterodimeric complex of TLR2 and TLR6. On receptor binding, MALP-2 activates the inflammatory pathways, such as MAPK and nuclear factor-κB, with subsequent release of cytokines, such as interleukin-6 and tumor necrosis factor-α. 16, 17 In the meantime, MALP-2 has even been successfully used for therapeutic applications in different experimental animals models (eg, for cancer immunotherapy) 36,37 as a mucosal adjuvant for vaccination, 18 for the induction of lipopolysaccharide cross-tolerance, 19 and for dermal wound healing. 11 Remarkably, clinical data for a therapeutic potential of MALP-2 are already available. Topically applied MALP-2 has been proved to be well tolerable when applied to the skin of volunteers in a phase 1 clinical trial 38 and exhibits beneficial effects in a phase 1/2 study with patients having developed aggressive pancreas adenocarcinoma. 39 In a vascular context, we have recently identified endothelial cells as target cells for MALP-2-dependent regenerative effects. We could delineate that MALP-2 promoted angiogenesis via a TLR2/6-dependent release of granulocyte macrophage colonystimulating factor by endothelial cells themselves, which we regard as a mechanism to restore capillaries in infected tissues to recruit immune cells for pathogen defense. 20 Our findings are in accordance with a study by West et al 14 showing that TLR2-knockout mice have impaired angiogenesis and endothelial cell migration. In the present study, we provide additional evidence that MALP-2 could be used for vascular regeneration. We observe that MALP-2 considerably promoted luminal reendothelialization and inhibited neointimal proliferation in experimental injury models of the carotid artery in mice. A unique systemic application of MALP-2 improves reendothelialization ≤3.5-fold. This seems not to be a general effect of TLR ligands, because other investigated TLR agonists did not improve reendothelialization. Interestingly, this also holds true for Pam 2 CSK 4 that signals via TLR2/6 just as MALP-2. Both ligands share a common lipid moiety but have different peptides. Sawahata et al 40 recently reported that Pam 2 CSK 4 but not MALP-2 is capable of activating natural killer cells. Potentially, their and our observations are based on the structural difference of these otherwise similar molecules. The observed discrepancy in our study between the effects of MALP-2 and the TLR2/1 ligand Pam 3 CSK 4 on reendothelialization is attributed to the fact that MALP-2 induces, beyond an overlapping pattern, distinct different inflammatory genes. 41 MALP-2 significantly enhanced proliferation and migration of endothelial cells but not of smooth muscle cells. Further mechanistic studies suggest that improved endothelial healing is mediated by an MALP-2-dependent release of multiple factors predominantly from endothelial cells, whereas smooth muscle cells did not release factors in response to MALP-2. These differences are the result of diminished MAPK activation in smooth muscle cells. Beyond effects on vascular cells, MALP-2 as well affects circulating blood cells. We observed an early increase especially in circulating monocytes and hematopoietic progenitor cells. Potentially, these cell populations contribute to the vascular healing process in a paracrine manner. The observed regenerative effect of MALP-2 after vascular injury seems to be in line with the before observed induction of angiogenesis by MALP-2. After bacterial infection, TLRs sense pathogen-associated molecular patterns such as MALP-2, and repair mechanisms, including angiogenesis and reendothelialization, are initiated to restore damaged tissue that could potentially be used for vascular therapeutic interventions. We here describe for the first time a novel therapeutic strategy for a toll-like receptor ligand in vascular wound healing. Especially the effect on reendothelialization may provide the opportunity to use macrophage-activating lipopeptide-2 for therapeutic endothelial wound healing after vascular injury. Improved ways of application, such as degradable bioabsorbable materials to release macrophage-activating lipopeptide-2 in a timely controlled manner adjacent to the site of endothelial denudation, should be tested. Furthermore, potentially additive effects of macrophage-activating lipopeptide-2 to promote reendothelialization and angiogenesis should be explored. Thus, further research using different experimental models of vascular injury preferably in larger animals is needed to confirm potentially beneficial effects of macrophage-activating lipopeptide-2 in vascular wound healing for future therapeutic applications in patients with vascular damage after interventional revascularization.
Significance
